|
Brain Research through Advancing Innovative Neurotechnologies Initiative (BRAIN Initiative)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NINDS, NCCIH, NEI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIMH, OD/DPCPSI/OBSSR
|
The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is revolutionizing our understanding of the brain by developing and applying innovative technologies to study brain circuits and, ultimately, to develop new ways to treat brain disorders. Circuits of brain cells enable us to think, perceive our world, and act upon it, and disruption of these circuits underlies neurological, psychiatric, and substance misuse disorders. The BRAIN Initiative also facilitates collaborative neuroscience research partnerships, resource meetings, and working groups.
|
|
BRIDG Standard Development
|
Research Initiative
|
FDA
|
NCI
|
Developing a conceptual data model that harmonize EMR data and protocol driven data
|
|
Bridge to Artificial Intelligence (Bridge2AI)
|
Research Initiative
|
FDA
|
OD/DPCPSI/OSC, NLM, NEI, NHGRI, NCCIH, NIBIB, NICHD, NCATS, NIMH, NIMHD, NIAID, NCI, NIAMS, NINDS, NIDA, NIA, NIGMS, FIC, OD/DPCPSI/OBSSR, OD/AoU, OD/DPCPSI/ODSS
|
The Bridge to Artificial Intelligence (Bridge2AI) program seeks to propel biomedical research forward by setting the stage for widespread adoption of artificial intelligence (AI) and machine learning (ML) that tackles complex biomedical challenges beyond human intuition. Bridge2AI works with representatives from the Defense Advanced Research Projects Agency (DARPA), U.S. Department of Energy (DOE), National Science Foundation (NSF), National Institute of Standards and Technology (NIST), and U.S. Food and Drug Administration (FDA) in order to bring expertise from across the federal government to help develop this groundbreaking new program that aims to harness the power of AI/ML for human health. Bridge2AI is also collaborating with DOE Office of Science program in Advanced Scientific Computing Research to jointly address important issues and challenges in developing AI and machine learning methods for privacy-sensitive datasets.
|
|
Build UP Trust Challenge Prize
|
Resource Development
|
CDC, HRSA, OASH
|
NHLBI, NIMHD, NCI, NIA, NIAID, NIEHS, NINDS, NCATS, NIAMS, NIBIB, NIDA, NICHD
|
The major objective of the Build UP Trust Challenge is to increase research participation, adoption of existing and new tools and strategies to detect, treat, and monitor diseases and disorders by improving engagement with underserved populations.
|
|
Canadian - U.S. Dietary Reference Intakes Working Group
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, OASH
|
OD/DPCPSI/ONR, NIDDK, OD/DPCPSI/ODS
|
The US and Canadian governments have each established Federal DRI Committees that work collaboratively to identify DRI needs and to coordinate government sponsorship of DRI reviews and related activities. The DRIs — which reflect nutrient reference values essential to national nutrition policies and to professionals working in the field of nutrition and health — have been developed under the auspices of the Institute of Medicine with funding from the US and Canadian governments.
|
|
Cancer Diagnostic Devices Interagency Task Force (CD2) - MOU among NCI, FDA, HRSA
|
Committee, Work group, Advisory group, or Task Force
|
FDA, HRSA
|
NCI
|
Interagency Task Force: On Friday, September 17, 2021, leadership from the National Cancer Institute (NCI), Food and Drug Administration (FDA), and Health Resources and Services Administration (HRSA) signed a Memorandum of Understanding (MOU) to support solutions for early cancer detection and diagnosis to improve patient outcomes, quality of life, and reduce health disparities among medically underserved, geographically isolated, and otherwise vulnerable populations. MOU formalizes the establishment of a new interagency task force, the Cancer Diagnostic Devices Interagency Task Force (CD2), which includes representatives from the NCI, FDA, and HRSA.
|
|
Cancer Moonshot Award
|
Research Initiative
|
OS
|
NIDCD, NCI
|
Cancer Moonshot Award to discover a panel of TCRs with various HLA restrictions for cancer and otolaryngic infectious disorders
|
|
CCDI Molecular Target Platform
|
Resource Development
|
FDA
|
NCI
|
The CCDI Molecular Targets Platform allows users to browse and identify associations between molecular targets, diseases, and drugs. The RACE Act requires evaluation of new molecularly targeted drugs and biologics intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of a pediatric cancer. This act also eliminates the orphan exemption for pediatric studies of cancer drugs directed at relevant molecular targets. In accordance with the RACE Act, the FDA, in collaboration with NCI and the pediatric cancer research community, developed a Relevant Molecular Target List (RMTL) to provide guidance to industry in planning for new drug and biologic submissions. NCI converted this RMTL list into a computer-readable format with gene-level granularity and all targets mapped and hyperlinked to additional resources and identifiers; integrated this list into Molecular Targets Platform.
|
|
CCR Vaccine Branch FACS Core
|
Research Initiative
|
FDA
|
NCI
|
CCR Vaccine Branch FACS Core
|
|
CCR, LGI, Flow Cytometry Core
|
Research Initiative
|
FDA
|
NCI
|
CCR, LGI, Flow Cytometry Core
|